Amber Y. Song

Amber Y. Song

Auto-generated profile, based on publicly available information

Amber Y. Song

Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Science Advances
Verified
Journal Article
Open access
TKTeha Kim
Teha Kim
LBLynn Bimler
Lynn Bimler
SRSydney Ronzulli
Sydney Ronzulli
ASAmber Y. Song
Amber Y. Song
SJScott K. Johnson
Scott K. Johnson
SPSilke Paust
Silke Paust
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e). Combined at low dose, this “triple M2e-mAb” confers robust prophylactic and therapeutic protection in mice challenged with diverse human and zoonotic IAV strains, including highly pathogenic variants. Therapeutic efficacy depends on Fc-mediated effector activity via FcγRI, FcγRIII, and FcγRIV, rather than in vitro neutralization. Serial passaging in triple M2e-mAb–treated immunocompetent and immunodeficient hosts failed to generate viral escape mutants. Our findings redefine the influenza-specific antibody therapeutic design and support Fc-optimized, non-neutralizing M2e-mAbs as a broadly effective, mutation-resistant, off-the-shelve therapy with direct relevance to human pandemic preparedness.